Omeros Corp. has received Orphan Drug designation from the FDA for OMS721 for prevention of complement-mediated thrombotic microangiopathies (TMAs). OMS721, the company’s lead human monoclonal antibody, targets mannan-binding lectin-associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system. TMAs, including atypical hemolytic uremic syndrome and thrombotic thrombocytopenic purpura, are a family of rare, debilitating and life-threatening disorders c...